SPARC and pachyonychia congenita: Interestingly, SPARC expressed in peritumoral fibroblasts has been shown to be correlated with a worse long-term prognosis in PC patients [39], which may partly explain the results of Han et al. Additionally, SPARC can also be used as a predictive biomarker in Nab-paclitaxel therapy.